NZ583193A - Treatment of post-traumatic stress disorder with nepicastat - Google Patents

Info

Publication number

NZ583193A

NZ583193A NZ583193A NZ58319308A NZ583193A NZ 583193 A NZ583193 A NZ 583193A NZ 583193 A NZ583193 A NZ 583193A NZ 58319308 A NZ58319308 A NZ 58319308A NZ 583193 A NZ583193 A NZ 583193A

Authority

NZ

New Zealand

Prior art keywords

nepicastat

dopamine

post

patient

stress disorder

Prior art date

2007-07-23

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 title claims abstract description 204
• 208000028173 post-traumatic stress disease Diseases 0.000 title claims abstract description 197
• YZZVIKDAOTXDEB-JTQLQIEISA-N nepicastat Chemical compound NCC1=CNC(=S)N1[C@@H]1CC2=CC(F)=CC(F)=C2CC1 YZZVIKDAOTXDEB-JTQLQIEISA-N 0.000 title description 381
• 229950005868 nepicastat Drugs 0.000 title description 376
• 239000003814 drug Substances 0.000 claims abstract description 69
• 239000000203 mixture Substances 0.000 claims abstract description 36
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 496
• 229960003638 dopamine Drugs 0.000 claims description 245
• 230000000694 effects Effects 0.000 claims description 205
• 208000024891 symptom Diseases 0.000 claims description 106
• 229940126062 Compound A Drugs 0.000 claims description 88
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 88
• 238000000034 method Methods 0.000 claims description 64
• 208000011580 syndromic disease Diseases 0.000 claims description 47
• 150000003943 catecholamines Chemical class 0.000 claims description 37
• 239000003795 chemical substances by application Substances 0.000 claims description 37
• 208000014674 injury Diseases 0.000 claims description 32
• 230000008733 trauma Effects 0.000 claims description 31
• 230000002093 peripheral effect Effects 0.000 claims description 29
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 24
• 210000004556 brain Anatomy 0.000 claims description 20
• 239000005557 antagonist Substances 0.000 claims description 16
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 16
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 16
• 230000006399 behavior Effects 0.000 claims description 15
• 239000011734 sodium Substances 0.000 claims description 15
• 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 14
• 239000000674 adrenergic antagonist Substances 0.000 claims description 14
• 239000000556 agonist Substances 0.000 claims description 14
• 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 14
• 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 14
• 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 14
• 230000002159 abnormal effect Effects 0.000 claims description 13
• OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 12
• 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims description 12
• 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims description 12
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 12
• 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 12
• 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 12
• 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 12
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 12
• 208000011117 substance-related disease Diseases 0.000 claims description 12
• 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 claims description 7
• 229940127291 Calcium channel antagonist Drugs 0.000 claims description 7
• 229940122459 Glutamate antagonist Drugs 0.000 claims description 7
• 229940122439 Hydroxylase inhibitor Drugs 0.000 claims description 7
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
• 239000002467 adenosine A2a receptor antagonist Substances 0.000 claims description 7
• 239000000695 adrenergic alpha-agonist Substances 0.000 claims description 7
• 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims description 7
• 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims description 7
• 230000001773 anti-convulsant effect Effects 0.000 claims description 7
• 230000001430 anti-depressive effect Effects 0.000 claims description 7
• 230000000561 anti-psychotic effect Effects 0.000 claims description 7
• 239000001961 anticonvulsive agent Substances 0.000 claims description 7
• 239000000935 antidepressant agent Substances 0.000 claims description 7
• 229940005513 antidepressants Drugs 0.000 claims description 7
• 229960003965 antiepileptics Drugs 0.000 claims description 7
• 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 7
• 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 7
• 239000000480 calcium channel blocker Substances 0.000 claims description 7
• 239000003825 glutamate receptor antagonist Substances 0.000 claims description 7
• 230000036961 partial effect Effects 0.000 claims description 7
• 229910052708 sodium Inorganic materials 0.000 claims description 7
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 6
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 6
• 108091006146 Channels Proteins 0.000 claims description 6
• 229940049706 benzodiazepine Drugs 0.000 claims description 6
• 229960002464 fluoxetine Drugs 0.000 claims description 6
• 229940044551 receptor antagonist Drugs 0.000 claims description 6
• 239000002464 receptor antagonist Substances 0.000 claims description 6
• 229940076279 serotonin Drugs 0.000 claims description 6
• 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 5
• 102100037346 Substance-P receptor Human genes 0.000 claims description 5
• 238000002560 therapeutic procedure Methods 0.000 claims description 5
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 4
• 208000007848 Alcoholism Diseases 0.000 claims description 4
• 206010013654 Drug abuse Diseases 0.000 claims description 4
• 206010001584 alcohol abuse Diseases 0.000 claims description 4
• 208000025746 alcohol use disease Diseases 0.000 claims description 4
• 230000007595 memory recall Effects 0.000 claims description 4
• 229960002296 paroxetine Drugs 0.000 claims description 4
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 4
• 108010074633 Mixed Function Oxygenases Proteins 0.000 claims description 3
• 102000008109 Mixed Function Oxygenases Human genes 0.000 claims description 3
• 206010029412 Nightmare Diseases 0.000 claims description 3
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 3
• 230000003252 repetitive effect Effects 0.000 claims description 3
• 229960002073 sertraline Drugs 0.000 claims description 3
• WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 2
• ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 2
• 229960002430 atomoxetine Drugs 0.000 claims description 2
• VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 2
• 229960001058 bupropion Drugs 0.000 claims description 2
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 2
• 229960001653 citalopram Drugs 0.000 claims description 2
• 229960002866 duloxetine Drugs 0.000 claims description 2
• 229960004341 escitalopram Drugs 0.000 claims description 2
• WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 2
• 229960001785 mirtazapine Drugs 0.000 claims description 2
• RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 2
• 229960004688 venlafaxine Drugs 0.000 claims description 2
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 abstract description 2
• DIPDUAJWNBEVOY-HNCPQSOCSA-N 4-(aminomethyl)-3-[(2r)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-1h-imidazole-2-thione;hydrochloride Chemical compound Cl.NCC1=CNC(=S)N1[C@H]1CC2=CC(F)=CC(F)=C2CC1 DIPDUAJWNBEVOY-HNCPQSOCSA-N 0.000 abstract 1
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 244
• 229960002748 norepinephrine Drugs 0.000 description 240
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 239
• 239000003981 vehicle Substances 0.000 description 162
• 241001465754 Metazoa Species 0.000 description 125
• 241000700159 Rattus Species 0.000 description 124
• 210000001519 tissue Anatomy 0.000 description 111
• 241000282472 Canis lupus familiaris Species 0.000 description 108
• 238000011699 spontaneously hypertensive rat Methods 0.000 description 84
• 239000000902 placebo Substances 0.000 description 81
• 229940068196 placebo Drugs 0.000 description 81
• 210000005240 left ventricle Anatomy 0.000 description 67
• 210000003975 mesenteric artery Anatomy 0.000 description 63
• 229940079593 drug Drugs 0.000 description 60
• 210000003710 cerebral cortex Anatomy 0.000 description 56
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 55
• 230000037023 motor activity Effects 0.000 description 47
• 230000002354 daily effect Effects 0.000 description 43
• 239000012458 free base Substances 0.000 description 43
• 230000007423 decrease Effects 0.000 description 40
• 230000036772 blood pressure Effects 0.000 description 38
• 239000003112 inhibitor Substances 0.000 description 36
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
• 238000004458 analytical method Methods 0.000 description 34
• 150000001875 compounds Chemical class 0.000 description 34
• DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 34
• 230000024188 startle response Effects 0.000 description 33
• 230000001965 increasing effect Effects 0.000 description 32
• 229910001868 water Inorganic materials 0.000 description 32
• 208000019901 Anxiety disease Diseases 0.000 description 31
• 239000002775 capsule Substances 0.000 description 31
• 210000002216 heart Anatomy 0.000 description 31
• 230000003389 potentiating effect Effects 0.000 description 31
• 230000004044 response Effects 0.000 description 31
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
• 206010019280 Heart failures Diseases 0.000 description 30
• 230000006872 improvement Effects 0.000 description 30
• 206010007559 Cardiac failure congestive Diseases 0.000 description 29
• 238000006243 chemical reaction Methods 0.000 description 29
• 230000009257 reactivity Effects 0.000 description 29
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
• 230000036506 anxiety Effects 0.000 description 27
• 238000012360 testing method Methods 0.000 description 27
• 102000004190 Enzymes Human genes 0.000 description 26
• 108090000790 Enzymes Proteins 0.000 description 26
• 229940088598 enzyme Drugs 0.000 description 26
• GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 25
• 229960002896 clonidine Drugs 0.000 description 25
• 230000036470 plasma concentration Effects 0.000 description 24
• 230000006977 prepulse inhibition Effects 0.000 description 24
• 239000000243 solution Substances 0.000 description 24
• 238000002474 experimental method Methods 0.000 description 23
• 230000033001 locomotion Effects 0.000 description 23
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 23
• 230000005764 inhibitory process Effects 0.000 description 22
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
• 230000037396 body weight Effects 0.000 description 20
• 238000004128 high performance liquid chromatography Methods 0.000 description 19
• 208000035475 disorder Diseases 0.000 description 18
• 230000006870 function Effects 0.000 description 18
• 230000009467 reduction Effects 0.000 description 18
• 230000002829 reductive effect Effects 0.000 description 18
• 210000002254 renal artery Anatomy 0.000 description 18
• WPMVQUHUCQAOBU-UHFFFAOYSA-N 3-[(3,5-difluorophenyl)methyl]-1h-imidazole-2-thione Chemical compound FC1=CC(F)=CC(CN2C(=NC=C2)S)=C1 WPMVQUHUCQAOBU-UHFFFAOYSA-N 0.000 description 17
• 238000003556 assay Methods 0.000 description 17
• 210000004369 blood Anatomy 0.000 description 17
• 239000008280 blood Substances 0.000 description 17
• 239000007788 liquid Substances 0.000 description 17
• 229960003732 tyramine Drugs 0.000 description 17
• 210000003462 vein Anatomy 0.000 description 17
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 16
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 16
• 238000000540 analysis of variance Methods 0.000 description 16
• 230000008859 change Effects 0.000 description 16
• 238000005259 measurement Methods 0.000 description 16
• 102000005962 receptors Human genes 0.000 description 16
• 108020003175 receptors Proteins 0.000 description 16
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
• 230000004872 arterial blood pressure Effects 0.000 description 15
• 230000001684 chronic effect Effects 0.000 description 15
• 230000003247 decreasing effect Effects 0.000 description 15
• 231100000673 dose–response relationship Toxicity 0.000 description 15
• 238000001727 in vivo Methods 0.000 description 15
• GOTMKOSCLKVOGG-OAHLLOKOSA-N (5R)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1([C@@H]2C3=CC(O)=C(Cl)C=C3CCN(C2)C)=CC=CC=C1 GOTMKOSCLKVOGG-OAHLLOKOSA-N 0.000 description 14
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
• 230000027455 binding Effects 0.000 description 14
• 238000009739 binding Methods 0.000 description 14
• 229910052757 nitrogen Inorganic materials 0.000 description 14
• 238000007619 statistical method Methods 0.000 description 14
• 230000035882 stress Effects 0.000 description 14
• 230000000472 traumatic effect Effects 0.000 description 14
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 13
• 101100499810 Bos taurus DBH gene Proteins 0.000 description 13
• 230000003276 anti-hypertensive effect Effects 0.000 description 13
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 13
• 238000002203 pretreatment Methods 0.000 description 13
• 150000003839 salts Chemical class 0.000 description 13
• 230000002889 sympathetic effect Effects 0.000 description 13
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
• 241000283690 Bos taurus Species 0.000 description 12
• RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 12
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
• 208000028017 Psychotic disease Diseases 0.000 description 12
• 230000003542 behavioural effect Effects 0.000 description 12
• 238000000835 electrochemical detection Methods 0.000 description 12
• -1 hydrochlorate Chemical class 0.000 description 12
• 230000003993 interaction Effects 0.000 description 12
• 238000001990 intravenous administration Methods 0.000 description 12
• 230000006742 locomotor activity Effects 0.000 description 12
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
• 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 11
• 230000001154 acute effect Effects 0.000 description 11
• 210000003748 coronary sinus Anatomy 0.000 description 11
• 238000009472 formulation Methods 0.000 description 11
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 11
• 238000001543 one-way ANOVA Methods 0.000 description 11
• 239000000523 sample Substances 0.000 description 11
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
• 241000699670 Mus sp. Species 0.000 description 10
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
• 235000010323 ascorbic acid Nutrition 0.000 description 10
• 239000011668 ascorbic acid Substances 0.000 description 10
• 230000009429 distress Effects 0.000 description 10
• PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 10
• 239000011780 sodium chloride Substances 0.000 description 10
• 241000282695 Saimiri Species 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 206010042458 Suicidal ideation Diseases 0.000 description 9
• 229940072107 ascorbate Drugs 0.000 description 9
• 230000008901 benefit Effects 0.000 description 9
• 229960000632 dexamfetamine Drugs 0.000 description 9
• 230000002526 effect on cardiovascular system Effects 0.000 description 9
• 235000019439 ethyl acetate Nutrition 0.000 description 9
• 239000000546 pharmaceutical excipient Substances 0.000 description 9
• 239000011541 reaction mixture Substances 0.000 description 9
• 210000002966 serum Anatomy 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 239000002904 solvent Substances 0.000 description 9
• 230000002269 spontaneous effect Effects 0.000 description 9
• 210000002820 sympathetic nervous system Anatomy 0.000 description 9
• 229960002178 thiamazole Drugs 0.000 description 9
• 102000016938 Catalase Human genes 0.000 description 8
• 108010053835 Catalase Proteins 0.000 description 8
• 241000282693 Cercopithecidae Species 0.000 description 8
• 238000001061 Dunnett's test Methods 0.000 description 8
• 101100499813 Homo sapiens DBH gene Proteins 0.000 description 8
• 239000007836 KH2PO4 Substances 0.000 description 8
• 238000005481 NMR spectroscopy Methods 0.000 description 8
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
• 238000009227 behaviour therapy Methods 0.000 description 8
• 230000015572 biosynthetic process Effects 0.000 description 8
• 239000000872 buffer Substances 0.000 description 8
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 8
• 229940105657 catalase Drugs 0.000 description 8
• 230000003292 diminished effect Effects 0.000 description 8
• 230000007717 exclusion Effects 0.000 description 8
• 235000019796 monopotassium phosphate Nutrition 0.000 description 8
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 8
• 229940001470 psychoactive drug Drugs 0.000 description 8
• 230000000306 recurrent effect Effects 0.000 description 8
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
• 230000002861 ventricular Effects 0.000 description 8
• 239000002253 acid Substances 0.000 description 7
• 150000001412 amines Chemical class 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 201000010099 disease Diseases 0.000 description 7
• 238000001647 drug administration Methods 0.000 description 7
• 235000013305 food Nutrition 0.000 description 7
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 7
• 229960003132 halothane Drugs 0.000 description 7
• 238000000338 in vitro Methods 0.000 description 7
• 230000002401 inhibitory effect Effects 0.000 description 7
• 210000001577 neostriatum Anatomy 0.000 description 7
• 238000003305 oral gavage Methods 0.000 description 7
• 229960001412 pentobarbital Drugs 0.000 description 7
• 239000013641 positive control Substances 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• 108050004812 Dopamine receptor Proteins 0.000 description 6
• 102000015554 Dopamine receptor Human genes 0.000 description 6
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
• 230000007488 abnormal function Effects 0.000 description 6
• 239000012491 analyte Substances 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 6
• 230000003001 depressive effect Effects 0.000 description 6
• 238000003745 diagnosis Methods 0.000 description 6
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
• 238000003306 harvesting Methods 0.000 description 6
• 230000000004 hemodynamic effect Effects 0.000 description 6
• 229920000669 heparin Polymers 0.000 description 6
• 229960002474 hydralazine Drugs 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 6
• 230000015654 memory Effects 0.000 description 6
• 238000012544 monitoring process Methods 0.000 description 6
• 230000007383 nerve stimulation Effects 0.000 description 6
• 238000013105 post hoc analysis Methods 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 238000011160 research Methods 0.000 description 6
• 238000001228 spectrum Methods 0.000 description 6
• 238000013222 sprague-dawley male rat Methods 0.000 description 6
• 238000012453 sprague-dawley rat model Methods 0.000 description 6
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
• 238000007492 two-way ANOVA Methods 0.000 description 6
• 238000005303 weighing Methods 0.000 description 6
• QHGUCRYDKWKLMG-QMMMGPOBSA-N (R)-octopamine Chemical compound NC[C@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-QMMMGPOBSA-N 0.000 description 5
• 238000012935 Averaging Methods 0.000 description 5
• 229920000858 Cyclodextrin Polymers 0.000 description 5
• 238000001135 Friedman test Methods 0.000 description 5
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• 206010020772 Hypertension Diseases 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 5
• 229920005372 Plexiglas® Polymers 0.000 description 5
• 206010037180 Psychiatric symptoms Diseases 0.000 description 5
• 108090000783 Renin Proteins 0.000 description 5
• 102100028255 Renin Human genes 0.000 description 5
• 238000000692 Student's t-test Methods 0.000 description 5
• 230000000747 cardiac effect Effects 0.000 description 5
• 238000004296 chiral HPLC Methods 0.000 description 5
• 230000002860 competitive effect Effects 0.000 description 5
• 238000013461 design Methods 0.000 description 5
• 229960002897 heparin Drugs 0.000 description 5
• 230000001631 hypertensive effect Effects 0.000 description 5
• 210000003246 kidney medulla Anatomy 0.000 description 5
• 229960001848 lamotrigine Drugs 0.000 description 5
• PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 5
• 238000004811 liquid chromatography Methods 0.000 description 5
• 238000007726 management method Methods 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 229960001576 octopamine Drugs 0.000 description 5
• 239000006187 pill Substances 0.000 description 5
• 102000004169 proteins and genes Human genes 0.000 description 5
• 108090000623 proteins and genes Proteins 0.000 description 5
• 235000021251 pulses Nutrition 0.000 description 5
• 238000010992 reflux Methods 0.000 description 5
• 230000029058 respiratory gaseous exchange Effects 0.000 description 5
• 238000003756 stirring Methods 0.000 description 5
• 239000006228 supernatant Substances 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 238000012353 t test Methods 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 210000001685 thyroid gland Anatomy 0.000 description 5
• 230000001550 time effect Effects 0.000 description 5
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
• DETXZQGDWUJKMO-UHFFFAOYSA-N 2-hydroxymethanesulfonic acid Chemical compound OCS(O)(=O)=O DETXZQGDWUJKMO-UHFFFAOYSA-N 0.000 description 4
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 4
• 206010066482 Exaggerated startle response Diseases 0.000 description 4
• 206010049666 Homicidal ideation Diseases 0.000 description 4
• 206010048533 Hypervigilance Diseases 0.000 description 4
• 206010022998 Irritability Diseases 0.000 description 4
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 4
• 102000004108 Neurotransmitter Receptors Human genes 0.000 description 4
• 108090000590 Neurotransmitter Receptors Proteins 0.000 description 4
• KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 4
• 238000001793 Wilcoxon signed-rank test Methods 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 210000001367 artery Anatomy 0.000 description 4
• 150000001540 azides Chemical class 0.000 description 4
• 208000028683 bipolar I disease Diseases 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 239000012267 brine Substances 0.000 description 4
• NMJJFJNHVMGPGM-UHFFFAOYSA-N butyl formate Chemical compound CCCCOC=O NMJJFJNHVMGPGM-UHFFFAOYSA-N 0.000 description 4
• 229960001948 caffeine Drugs 0.000 description 4
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 4
• 229960000623 carbamazepine Drugs 0.000 description 4
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• 208000010877 cognitive disease Diseases 0.000 description 4
• 230000000875 corresponding effect Effects 0.000 description 4
• 229940063223 depo-provera Drugs 0.000 description 4
• 238000010828 elution Methods 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 238000001704 evaporation Methods 0.000 description 4
• 210000003191 femoral vein Anatomy 0.000 description 4
• 238000003304 gavage Methods 0.000 description 4
• 230000001077 hypotensive effect Effects 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• 239000011630 iodine Substances 0.000 description 4
• 229910052740 iodine Inorganic materials 0.000 description 4
• 238000007449 liver function test Methods 0.000 description 4
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• CXGFWBPQQXZELI-UHFFFAOYSA-N n-ethylpyridin-2-amine Chemical compound CCNC1=CC=CC=N1 CXGFWBPQQXZELI-UHFFFAOYSA-N 0.000 description 4
• 229960002715 nicotine Drugs 0.000 description 4
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
• 150000002825 nitriles Chemical class 0.000 description 4
• 239000003539 oral contraceptive agent Substances 0.000 description 4
• 238000013439 planning Methods 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 239000004089 psychotropic agent Substances 0.000 description 4
• 230000008327 renal blood flow Effects 0.000 description 4
• 239000000837 restrainer Substances 0.000 description 4
• 230000033764 rhythmic process Effects 0.000 description 4
• 230000035945 sensitivity Effects 0.000 description 4
• 210000000697 sensory organ Anatomy 0.000 description 4
• 238000000926 separation method Methods 0.000 description 4
• 239000000377 silicon dioxide Substances 0.000 description 4
• AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 4
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
• 201000009032 substance abuse Diseases 0.000 description 4
• 231100000736 substance abuse Toxicity 0.000 description 4
• 201000006152 substance dependence Diseases 0.000 description 4
• 230000003319 supportive effect Effects 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 230000035488 systolic blood pressure Effects 0.000 description 4
• 229940034208 thyroxine Drugs 0.000 description 4
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 4
• 229960004394 topiramate Drugs 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 229940102566 valproate Drugs 0.000 description 4
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
• DZGWFCGJZKJUFP-ZQBYOMGUSA-N 4-(2-aminoethyl)phenol Chemical compound N[14CH2]CC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-ZQBYOMGUSA-N 0.000 description 3
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
• 108060003345 Adrenergic Receptor Proteins 0.000 description 3
• 102000017910 Adrenergic receptor Human genes 0.000 description 3
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
• 241000189705 Dunedin group Species 0.000 description 3
• 108010061435 Enalapril Proteins 0.000 description 3
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
• 239000005977 Ethylene Substances 0.000 description 3
• 108010024636 Glutathione Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 206010022035 Initial insomnia Diseases 0.000 description 3
• 206010029260 Neuroblastoma Diseases 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
• 230000005534 acoustic noise Effects 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 239000008346 aqueous phase Substances 0.000 description 3
• 230000036760 body temperature Effects 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• 230000035487 diastolic blood pressure Effects 0.000 description 3
• 239000012153 distilled water Substances 0.000 description 3
• 229940000406 drug candidate Drugs 0.000 description 3
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 3
• 229960000873 enalapril Drugs 0.000 description 3
• 230000008020 evaporation Effects 0.000 description 3
• 230000003203 everyday effect Effects 0.000 description 3
• 239000003777 experimental drug Substances 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 229960003180 glutathione Drugs 0.000 description 3
• 244000144993 groups of animals Species 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 210000004731 jugular vein Anatomy 0.000 description 3
• 210000000231 kidney cortex Anatomy 0.000 description 3
• 238000010150 least significant difference test Methods 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 238000012417 linear regression Methods 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 235000019198 oils Nutrition 0.000 description 3
• 239000012074 organic phase Substances 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 239000008194 pharmaceutical composition Substances 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
• 229920000053 polysorbate 80 Polymers 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 208000020016 psychiatric disease Diseases 0.000 description 3
• 230000001568 sexual effect Effects 0.000 description 3
• 238000000527 sonication Methods 0.000 description 3
• 239000012089 stop solution Substances 0.000 description 3
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
• 238000004809 thin layer chromatography Methods 0.000 description 3
• 238000004448 titration Methods 0.000 description 3
• 238000012384 transportation and delivery Methods 0.000 description 3
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 3
• 238000000825 ultraviolet detection Methods 0.000 description 3
• 238000011706 wistar kyoto rat Methods 0.000 description 3
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
• YFMPSMITLLBENU-UHFFFAOYSA-N 3,4-dihydroxybenzylamine Chemical compound NCC1=CC=C(O)C(O)=C1 YFMPSMITLLBENU-UHFFFAOYSA-N 0.000 description 2
• ZKPVULIWDZEZIT-UHFFFAOYSA-N 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)pyridine Chemical compound C1CC2=CC=CC=C2C(CC)=C1C1=CC=CN=C1 ZKPVULIWDZEZIT-UHFFFAOYSA-N 0.000 description 2
• HOUVATQQKYAEBB-UHFFFAOYSA-N 5,7-difluoro-3,4-dihydro-1h-naphthalen-2-one Chemical compound C1CC(=O)CC2=CC(F)=CC(F)=C21 HOUVATQQKYAEBB-UHFFFAOYSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• 102000008146 Acetate-CoA ligase Human genes 0.000 description 2
• 108010049926 Acetate-CoA ligase Proteins 0.000 description 2
• UMQUQWCJKFOUGV-UHFFFAOYSA-N CGP 12177 Chemical compound CC(C)(C)NCC(O)COC1=CC=CC2=C1NC(=O)N2 UMQUQWCJKFOUGV-UHFFFAOYSA-N 0.000 description 2
• 102000000584 Calmodulin Human genes 0.000 description 2
• 108010041952 Calmodulin Proteins 0.000 description 2
• 206010048964 Carotid artery occlusion Diseases 0.000 description 2
• 102000010906 Cyclooxygenase 1 Human genes 0.000 description 2
• 108010037464 Cyclooxygenase 1 Proteins 0.000 description 2
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• DGMPVYSXXIOGJY-UHFFFAOYSA-N Fusaric acid Chemical compound CCCCC1=CC=C(C(O)=O)N=C1 DGMPVYSXXIOGJY-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 238000010268 HPLC based assay Methods 0.000 description 2
• 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
• 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
• 102100037611 Lysophospholipase Human genes 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 125000003047 N-acetyl group Chemical group 0.000 description 2
• 238000011887 Necropsy Methods 0.000 description 2
• 108090000028 Neprilysin Proteins 0.000 description 2
• 102000003729 Neprilysin Human genes 0.000 description 2
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
• GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
• 108010058864 Phospholipases A2 Proteins 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
• 241000700157 Rattus norvegicus Species 0.000 description 2
• 206010039203 Road traffic accident Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 241000282696 Saimiri sciureus Species 0.000 description 2
• 229940124639 Selective inhibitor Drugs 0.000 description 2
• 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 2
• 108010054082 Sterol O-acyltransferase Proteins 0.000 description 2
• 102000010861 Type 3 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
• 108010037543 Type 3 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
• 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
• 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
• 230000003187 abdominal effect Effects 0.000 description 2
• YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 210000004100 adrenal gland Anatomy 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
• 229910052786 argon Inorganic materials 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 230000004531 blood pressure lowering effect Effects 0.000 description 2
• 238000010241 blood sampling Methods 0.000 description 2
• 230000000059 bradycardiac effect Effects 0.000 description 2
• NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
• 229960004195 carvedilol Drugs 0.000 description 2
• YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
• 238000010835 comparative analysis Methods 0.000 description 2
• 230000036757 core body temperature Effects 0.000 description 2
• 238000013480 data collection Methods 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 239000008367 deionised water Substances 0.000 description 2
• 229910021641 deionized water Inorganic materials 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical group CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 238000007824 enzymatic assay Methods 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 150000002148 esters Chemical group 0.000 description 2
• 230000000763 evoking effect Effects 0.000 description 2
• 210000001105 femoral artery Anatomy 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
• 230000000574 ganglionic effect Effects 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• AKRQHOWXVSDJEF-UHFFFAOYSA-N heptane-1-sulfonic acid Chemical compound CCCCCCCS(O)(=O)=O AKRQHOWXVSDJEF-UHFFFAOYSA-N 0.000 description 2
• 125000000623 heterocyclic group Chemical group 0.000 description 2
• ARRNBPCNZJXHRJ-UHFFFAOYSA-M hydron;tetrabutylazanium;phosphate Chemical compound OP(O)([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC ARRNBPCNZJXHRJ-UHFFFAOYSA-M 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 238000010829 isocratic elution Methods 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 230000003907 kidney function Effects 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 230000005923 long-lasting effect Effects 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 230000003340 mental effect Effects 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 230000018791 negative regulation of catalytic activity Effects 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 230000002644 neurohormonal effect Effects 0.000 description 2
• 230000003982 neuronal uptake Effects 0.000 description 2
• 239000002858 neurotransmitter agent Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000012044 organic layer Substances 0.000 description 2
• 229960001816 oxcarbazepine Drugs 0.000 description 2
• CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
• 208000019906 panic disease Diseases 0.000 description 2
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
• 229960001802 phenylephrine Drugs 0.000 description 2
• SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
• 239000004926 polymethyl methacrylate Substances 0.000 description 2
• 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 2
• ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
• 229960001289 prazosin Drugs 0.000 description 2
• IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
• 230000036584 pressor response Effects 0.000 description 2
• 150000003140 primary amides Chemical class 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• 238000001671 psychotherapy Methods 0.000 description 2
• 210000001147 pulmonary artery Anatomy 0.000 description 2
• 239000013062 quality control Sample Substances 0.000 description 2
• 238000003653 radioligand binding assay Methods 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• 210000003752 saphenous vein Anatomy 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 229940125794 sodium channel blocker Drugs 0.000 description 2
• 239000003195 sodium channel blocking agent Substances 0.000 description 2
• 230000000392 somatic effect Effects 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 238000000528 statistical test Methods 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 229940095064 tartrate Drugs 0.000 description 2
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• 238000000844 transformation Methods 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 230000024883 vasodilation Effects 0.000 description 2
• 239000000341 volatile oil Substances 0.000 description 2
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
• OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
• XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
• GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 1
• IGGNSAVLXJKCNH-UHFFFAOYSA-N 2-(3,5-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(F)=CC(F)=C1 IGGNSAVLXJKCNH-UHFFFAOYSA-N 0.000 description 1
• WMVPARKLYWQLNN-UHFFFAOYSA-N 2-(3,5-difluorophenyl)acetyl chloride Chemical compound FC1=CC(F)=CC(CC(Cl)=O)=C1 WMVPARKLYWQLNN-UHFFFAOYSA-N 0.000 description 1
• IVHKZCSZELZKSJ-UHFFFAOYSA-N 2-hydroxyethyl sulfonate Chemical compound OCCOS(=O)=O IVHKZCSZELZKSJ-UHFFFAOYSA-N 0.000 description 1
• 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
• RNISDHSYKZAWOK-LGUBBEMLSA-N 4-(2-aminoethyl)phenol;hydrochloride Chemical compound Cl.N[14CH2]CC1=CC=C(O)C=C1 RNISDHSYKZAWOK-LGUBBEMLSA-N 0.000 description 1
• 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
• 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
• 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
• 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
• 102100021879 Adenylyl cyclase-associated protein 2 Human genes 0.000 description 1
• 101710137132 Adenylyl cyclase-associated protein 2 Proteins 0.000 description 1
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 244000208874 Althaea officinalis Species 0.000 description 1
• 235000006576 Althaea officinalis Nutrition 0.000 description 1
• 102000005862 Angiotensin II Human genes 0.000 description 1
• 101800000733 Angiotensin-2 Proteins 0.000 description 1
• 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
• 229930003347 Atropine Natural products 0.000 description 1
• 208000020925 Bipolar disease Diseases 0.000 description 1
• 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 102000006378 Catechol O-methyltransferase Human genes 0.000 description 1
• 108020002739 Catechol O-methyltransferase Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 101150049660 DRD2 gene Proteins 0.000 description 1
• 206010012374 Depressed mood Diseases 0.000 description 1
• HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 206010016275 Fear Diseases 0.000 description 1
• 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
• 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
• 206010017577 Gait disturbance Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000011688 Generalised anxiety disease Diseases 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
• 102000011845 Iodide peroxidase Human genes 0.000 description 1
• 108010036012 Iodide peroxidase Proteins 0.000 description 1
• 238000012313 Kruskal-Wallis test Methods 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
• 244000043158 Lens esculenta Species 0.000 description 1
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010029216 Nervousness Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
• 102000003840 Opioid Receptors Human genes 0.000 description 1
• 108090000137 Opioid Receptors Proteins 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010033664 Panic attack Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 208000004880 Polyuria Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 101710171573 Primary amine oxidase Proteins 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
• 229910006124 SOCl2 Inorganic materials 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 206010041349 Somnolence Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 238000007059 Strecker synthesis reaction Methods 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 208000001871 Tachycardia Diseases 0.000 description 1
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 208000028752 abnormal posture Diseases 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 150000007513 acids Chemical group 0.000 description 1
• 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 229960001570 ademetionine Drugs 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
• 230000008484 agonism Effects 0.000 description 1
• 229960002478 aldosterone Drugs 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 125000005219 aminonitrile group Chemical group 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
• 229960002519 amoxapine Drugs 0.000 description 1
• QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 239000000538 analytical sample Substances 0.000 description 1
• 229950006323 angiotensin ii Drugs 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000001078 anti-cholinergic effect Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 230000000338 anxiogenic effect Effects 0.000 description 1
• 210000000702 aorta abdominal Anatomy 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 229960004372 aripiprazole Drugs 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
• 229960000396 atropine Drugs 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 238000012742 biochemical analysis Methods 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 238000012754 cardiac puncture Methods 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 238000000451 chemical ionisation Methods 0.000 description 1
• 231100000762 chronic effect Toxicity 0.000 description 1
• 238000010549 co-Evaporation Methods 0.000 description 1
• 238000009225 cognitive behavioral therapy Methods 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000012230 colorless oil Substances 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000009989 contractile response Effects 0.000 description 1
• 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000005574 cross-species transmission Effects 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000000586 desensitisation Methods 0.000 description 1
• 229960003914 desipramine Drugs 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 230000003205 diastolic effect Effects 0.000 description 1
• WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
• 235000020805 dietary restrictions Nutrition 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 229960002563 disulfiram Drugs 0.000 description 1
• 230000035619 diuresis Effects 0.000 description 1
• 230000003291 dopaminomimetic effect Effects 0.000 description 1
• 229960005426 doxepin Drugs 0.000 description 1
• ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
• 239000003651 drinking water Substances 0.000 description 1
• 235000020188 drinking water Nutrition 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 230000000857 drug effect Effects 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 230000003028 elevating effect Effects 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 150000002084 enol ethers Chemical group 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 230000004424 eye movement Effects 0.000 description 1
• 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 230000012953 feeding on blood of other organism Effects 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 210000001652 frontal lobe Anatomy 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 108010074605 gamma-Globulins Proteins 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 208000029364 generalized anxiety disease Diseases 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 230000036433 growing body Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 239000012456 homogeneous solution Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 150000004677 hydrates Chemical group 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 229960004801 imipramine Drugs 0.000 description 1
• BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 238000002329 infrared spectrum Methods 0.000 description 1
• 230000030214 innervation Effects 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 229940039009 isoproterenol Drugs 0.000 description 1
• IQVRBWUUXZMOPW-PKNBQFBNSA-N istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 description 1
• 229950009028 istradefylline Drugs 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 238000009533 lab test Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229960004002 levetiracetam Drugs 0.000 description 1
• HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 235000001035 marshmallow Nutrition 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 206010027175 memory impairment Diseases 0.000 description 1
• 230000004630 mental health Effects 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• 229940073569 n-methylephedrine Drugs 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000030564 negative regulation of blood pressure Effects 0.000 description 1
• 230000008035 nerve activity Effects 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 239000001272 nitrous oxide Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 230000002474 noradrenergic effect Effects 0.000 description 1
• 229960001158 nortriptyline Drugs 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 238000007427 paired t-test Methods 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229960002275 pentobarbital sodium Drugs 0.000 description 1
• 230000036581 peripheral resistance Effects 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 238000011170 pharmaceutical development Methods 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 208000019899 phobic disease Diseases 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 230000036544 posture Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 229930010796 primary metabolite Natural products 0.000 description 1
• 238000011809 primate model Methods 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Chemical group 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 229960004431 quetiapine Drugs 0.000 description 1
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 239000002287 radioligand Substances 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 230000036454 renin-angiotensin system Effects 0.000 description 1
• 238000012958 reprocessing Methods 0.000 description 1
• 238000012827 research and development Methods 0.000 description 1
• QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 229960001534 risperidone Drugs 0.000 description 1
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
• 229960003014 rufinamide Drugs 0.000 description 1
• POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
• 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 231100000161 signs of toxicity Toxicity 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 238000011947 six minute walk test Methods 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000012064 sodium phosphate buffer Substances 0.000 description 1
• 239000001476 sodium potassium tartrate Substances 0.000 description 1
• 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
• 239000012453 solvate Chemical group 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 230000000153 supplemental effect Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002782 sympathoadrenal effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 230000006794 tachycardia Effects 0.000 description 1
• 230000000213 tachycardiac effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 229940035722 triiodothyronine Drugs 0.000 description 1
• 229960002431 trimipramine Drugs 0.000 description 1
• ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• XREXPQGDOPQPAH-QKUPJAQQSA-K trisodium;[(z)-18-[1,3-bis[[(z)-12-sulfonatooxyoctadec-9-enoyl]oxy]propan-2-yloxy]-18-oxooctadec-9-en-7-yl] sulfate Chemical compound [Na+].[Na+].[Na+].CCCCCCC(OS([O-])(=O)=O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O)COC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O XREXPQGDOPQPAH-QKUPJAQQSA-K 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
• 229960001844 tubocurarine Drugs 0.000 description 1
• 238000002211 ultraviolet spectrum Methods 0.000 description 1
• 230000036325 urinary excretion Effects 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000000304 vasodilatating effect Effects 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003039 volatile agent Substances 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 229940020965 zoloft Drugs 0.000 description 1